Drs. H. Jack West, Joan Schiller, and Isabel Preeshagul gathered (virtually) to review information presented at ASCO and ESMO for 2021.
For this series, the doctors discuss new trials for patients with NSCLC. In this video, the doctors discuss the MYLUNG Consortium and overall biomarker testing, as presented at the 2021 ASCO Annual Meeting.
The MYLUNG study focused on U.S. Oncology Network community practices, where rates of patients having been tested for five major biomarkers (ALK, BRAF, EGFR, PD-L1, and ROS-1) show as less than 50%. A second study also showed that 39% of Black patients with metastatic NSCLC underwent next-generation sequencing compared with 50% of their White counterparts, noting also the effect on clinical trial enrollment.
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.